AzTrials
AzTrials

Post-Hemorrhagic HydrocephalusNCT00747682

Cerebral Perfusion, Oxygenation, Electrical Activity

An observational study of Post-Hemorrhagic Hydrocephalus, run by University of Utah at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The specific aim of the research proposal in preterm infants with IVH and PHH who require placement of an Omaya reservoir or a shunt is to determine if decreasing ventricular volume improves, middle cerebral artery flow, cerebral oxygenation, and cortical neuronal electrical activity. Read more about this study

Who is it for?
Any age
Conditions the study is for
Post-Hemorrhagic Hydrocephalus
How many people
30 participants
Where
1 siteUnited States
Study dates
Jul 2006to Aug 2009
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Any age
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

Study population: Infants enrolled in this study will be identified at the time of neurosurgical evaluation for placement of a shunt or an Omaya reservoir for post-hemorrhagic hydrocephalus. Infants who have received vasoactive drugs (e.g. non-steroidal anti-inflammatory, dopamine, dobutamine, epinephrine, etc), will not be excluded from the study but the measurements will be postponed until 72 hrs after discontinuation of the medications.

Who may be able to join

  • Infants enrolled in this study will be identified at the time of neurosurgical evaluation for placement of a shunt or an Omaya reservoir for post-hemorrhagic hydrocephalus. Infants who have received vasoactive drugs (e.g. non-steroidal anti-inflammatory, dopamine, dobutamine, epinephrine, etc), will not be excluded from the study but the measurements will be postponed until 72 hrs after discontinuation of the medications.

Who cannot join

None listed.

Trial locations and contacts

1 site in 1 country.

United States1 site
  • University of Utah

    Salt Lake City, Utah, 84132

Other trials in United States

About this study

Official title: Alterations in Cerebral Perfusion, Oxygenation, Electrical Activity, and Markers of Cerebral Damage Associated With Cerebro-spinal Fluid Reservior Aspiration in Neonates With Post Hemorrhagic Hydrocephalus

The specific aim of the research proposal in preterm infants with IVH and PHH who require placement of an Omaya reservoir or a shunt is to determine if decreasing ventricular volume improves, middle cerebral artery flow, cerebral oxygenation, and cortical neuronal electrical activity. To accomplish this aim, we will simultaneously perform the following evaluations prior to shunt placement or prior to and after routine CSF aspiration from reservoir in:

  1. middle cerebral artery velocity time integral and resistive index using Doppler ultrasonography
  2. cerebral oxygenation using near infrared spectroscopy (NIRS)
  3. background neuronal electrical activity using an EEG. In addition, we will measure serial CSF concentration of neuroproteins, S100B, GFAP, NSE, TGF-ß, and IL-6, as evidence of ongoing neuronal damage and correlate the concentration with cerebral perfusion and activity as measured above.
Read the detailed description

Very low birth weight infants are at risk for developing intraventricular hemorrhage (IVH). Post hemorrhagic hydrocephalus (PPH) is a major complication of IVH and contributes to long-term developmental delays. Progressive PHH often requires management of ventricular dilation by adjusting CSF fluid volume. There are 3 methods employed to acutely decrease CSF volume: 1) serial lumbar puncture, 2) open drain system (continuous CSF removal), and 3) reservoir system. Serial lumbar puncture is only effective if there is communicating hydrocephalus. The open drain system is infrequently used as it is cumbersome and there is a relatively high risk of infection. The method most commonly used to manage CSF volume is the reservoir system where an in-situ drain is connected to a subcutaneous (Omaya) reservoir which is periodically aspirated by needle puncture through the scalp. Because the Omaya system is closed, intraventricular volume and, thus, pressure must necessarily rise prior to and decrease after CSF aspiration. Ventricular dilation is controlled by the frequency and volume of CSF aspiration.

When hydrocephalus continues to be a problem despite removal of CSF, a ventricular-peritoneal (VP) shunt is placed. Approximately 50% of infants with hydrocephalus treated with removal of CSF resolve their hydrocephalus and do not require VP shunt placement. Placement of a VP shunt is difficult in extremely preterm infants due to increased risk of ulceration around the shunt site and the high protein concentration in CSF which can occlude the valve in the VP shunt requiring revision. Thus, hydrocephalus is usually treated with serial removal of CSF to allow for identification of those infant's whose hydrocephalus resolves over time. However, timing and method of CSF management is controversial because the effect of increasing hydrocephalus on cerebral perfusion, oxygenation, electrical activity, and neuronal damage has not been established.

Serial removal of CSF causes a change in intracranial volume/pressure that can be potentially transmitted to intracranial vessels. The caliber of cerebral vessels may be modified by this balance between intravascular and intracranial pressure, and if the caliber should change, the blood flow characteristics should also change. In cerebral veins and capillaries where intraluminal pressure is low, high intraventricular pressure may significantly affect blood flow and can cause venous stasis. NIRS measures cerebral oxygenation in capillaries and veins. Intracranial arteries and arterioles may be somewhat less affected, except when intraventricular pressure greatly increases. The resultant decrease in the arterial supply can affect tissue perfusion. Arterial flow can be measured by Doppler ultrasonography. Thus, there is concern that during periods of increasing or fluctuating ventricular size cerebral arterial perfusion may be compromised and further cerebral injury may result. Intracranial pressure is further influenced by the plasticity/deformability of the immature brain and the easy expansibility of the cranial vault due to the presence of sutures and open fontanelles.

There is indirect evidence from experiments in animals that ventricular distention itself may cause secondary brain injury. Thus, axonal stretching and disruption secondary to progressive ventriculomegaly is be associated with gliosis. Periventricular vascular distortion and compression may decrease cerebral blood flow causing ischemic injury to periventricular white matter. Inflammation and repair may interfere with CSF flow.

Little research is available that helps answer the primary question involved in clinical management of ventricular dilation in premature infants: Are there relationships between ventricular enlargement, cerebral perfusion, brain oxygen delivery, and on-going cerebral damage?

Doppler ultrasonography has been applied in premature infants to characterize post delivery changes in arterial and venous cerebral blood flow velocities.[1] Critically low superior vena cava flow measured by Doppler ultrasonography in the first 24 hours of life has been associated with intraventricular hemorrhage in premature infants born before 30 weeks gestation.[2] Using pulsed Doppler ultrasonography, the resistive index can be measured which is a inversely related to blood flow. In older infants with established hydrocephalus, cerebral blood flow resistive index appeared to be a good indicator of increased intracranial pressure.[3] However, in a review article, the value of Doppler indices alone in predicting increased intracranial pressure was strongly questioned.[4] In a recent article, the resistive index of the anterior cerebral artery decreased significantly after CSF drainage in infants with PHH. [5] Although Doppler ultrasonography is easy to perform, its role in detecting significant changes in cerebral perfusion associated with increased CSF volume and ventricular dilation is not yet established.

Near infrared spectroscopy (NIRS) is a portable non-invasive technique used to measure regional cerebral oxygen saturation in cerebral blood.[6] NIRS has been used to evaluate effect of head [7] and body position [8] on cerebral hemodynamics in preterm infants, and the effect of certain treatments, such as surfactant administration [9] and suctioning on conventional or high-frequency ventilation.[10] NIRS measurement of cerebral oxygenation and hemodynamics shows impairment in those neonates at risk for developing severe brain ischemia.[11] In premature infants with PHH, CSF fluid aspiration was associated with a significant increase in cerebral perfusion, cerebral blood volume, and oxidative metabolism.[12,13] In a small animal model of acute hydrocephalus, NIRS measurement of global cerebral blood flow using oxygen as a tracer was highly correlated to cerebral blood flow measured by radioactive microspheres over a wide range of increased intracranial pressure.[14] As intracranial pressure increased, NIRS measurement and absolute measurement of cerebral blood flow decreased. NIRS measured cerebral perfusion appears to directly reflect absolute cerebral blood flow and is sensitive enough to detect significant changes in cerebral perfusion which occur with evacuation of CSF in infants with PHH.

Amplitude-integrated EEG (aEEG) is a device used for neurologic surveillance. The cortical electrical activity is transformed into a single signal that represents overall electrocortical background activity of the brain. Specifically the upper and lower voltage margins and the amplitude of the tracing and the presence of seizure activity can be evaluated. In addition, the presence of sleep-wake cycles, a rhythmic sinusoidal variation in amplitude, can be evaluated. Infants > 34 weeks gestation have predictable aEEG patterns. The signal depends on gestational age and postnatal age and standards for preterm infants have been reported.[15,16] In a case report, 2 preterm infants with PHH demonstrated abnormal sleep-wake cycles and markedly decreased cerebral electrical activity with increasing ventricular enlargement prior to clinical signs of increased intracranial pressure. In one infant, aEEG normalized after VP shunt placement.[17] To date, there are no clinical studies on the effect of aspiration of CSF on aEEG in preterm infants with PHH.

Biomarkers for cerebral injury have been used to predict severity of injury and long-term outcome, identify patients early at risk for poor neurologic outcomes, and evaluate effectiveness of therapeutic interventions. Neuronal specific enolase (NSE), a marker for neuronal damage, and S100B, secreted by astrocytes and a marker of glial/neuronal injury, have been shown to be increased in children after traumatic brain injury.[18] In preterm infants with PHH, S100B and glial fibrillary acid protein (GFAP), a structural protein in astrocytes, were significantly elevated in those infants who had brain parenchymal lesions and poor neurological outcomes.[19] These biomarkers are quickly metabolized and thus ongoing elevation would indicate ongoing damage. Transforming growth factor beta (TGF-ß), produced by fibroblasts and released into the CSF after injury, stimulates production of extracellular protein which could result in PHH due to a permanent obstruction to CSF flow.[20] Cytokine IL-6 is a marker of inflammation. There are no longitudinal studies on the effect of aspiration of CSF on these markers of cerebral damage in preterm infants with PHH.

Keywords
Cerebral Perfusion,, Oxygenation,, Electrical, Activity
Medical subject headings
Motor Activity

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Determine if decreasing ventricular volume improves middle cerebral artery flow, cerebral oxygenation, and cortical neuronal electrical activity.

    Measured: 1 year

Secondary outcomes (1)
  1. To correlate CSF concentration of neuroproteins, S100B, GFAP, NSE, TGF-beta, and IL-6 with cerebral perfusion and neuronal electrical activity.

    Measured: 1 year

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted5 Sep 2008 (estimated)
  2. Study startJul 2006
  3. Primary completionMay 2009
  4. Study completionAug 2009

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Retrospective
Enrolment
30 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00747682
Sponsor's protocol ID
18833
Status last verified
Jun 2010
First submitted
3 Sep 2008
Last updated
24 Jun 2010
Results posted
No
Data monitoring committee
No

Questions about this trial

What is this clinical trial studying?

An observational study of Post-Hemorrhagic Hydrocephalus, run by University of Utah at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 0 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 24 Jun 2010. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Determine if decreasing ventricular volume improves middle cerebral artery flow, cerebral oxygenation, and cortical neuronal electrical activity. (time frame: 1 year). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Jun 2010.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in